# Nuohong Huikang

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/nuohong-huikang

- Industry: Biotechnology
- Headquarters: Chengdu, China
- Total disclosed funding: $15M
- Latest round: Series A (May 25, 2026)
- Investors on record: 3

## About

Based in China and founded in 2023, Sichuan Nuohong Huikang Biotechnology Co., Ltd., trading as Nuohong Huikang, provides biopharmaceutical reagent development and related services for the cell and gene therapy (CGT) and life sciences industry. In May 2026, it raised approximately CNY 100 million in series A funding. Nuohong Huikang develops biotechnology products centered on cell biology and CGT upstream reagents, offering solutions including cell culture media, serum substitutes, stem cell and immune cell culture systems, and laboratory reagents, while focusing on high-purity, chemically defined formulations and customizable reagent systems, enabling applications across biomedical research, cell therapy, vaccine and antibody development, diagnostics, and synthetic biology. The company has developed a portfolio of cell culture products for MSC, NK, organoid, and iPSC applications, covering multiple stages of research and industrialization. The company generates revenue primarily through sales of biotechnology reagents and consumables, as well as process development, manufacturing, and technical service offerings for biopharmaceutical clients and research institutions. The company will use the series A funding to expand its GMP production base in Luzhou, establish a subsidiary in the Yangtze River Delta region, further enhance the research and development of new products, and rapidly promote multiple products in the global market.

## Funding rounds

- Series A, May 25, 2026, $15M — Zero2IPO Fund of Funds, Empower Investment, Luzhou Gongtou Equity Investment Fund Management

## Investors

- Zero2IPO Fund of Funds (https://capitalatlas.ai/funds/zero2ipo-fund-of-funds) — Series A
- Empower Investment (https://capitalatlas.ai/funds/empower-investment) — Series A
- Luzhou Gongtou Equity Investment Fund Management (https://capitalatlas.ai/funds/luzhou-gongtou-equity-investment-fund-management) — Series A